Palvella Therapeutics (NASDAQ:PVLA) Given New $270.00 Price Target at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently issued reports on PVLA. BTIG Research raised their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Canaccord Genuity Group upped their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Craig Hallum initiated coverage on Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Finally, Chardan Capital restated a “buy” rating and set a $210.00 price objective on shares of Palvella Therapeutics in a research note on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $195.93.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $116.23 on Tuesday. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The firm’s 50-day moving average is $103.69 and its 200-day moving average is $89.54. The company has a market cap of $1.38 billion, a P/E ratio of -44.19 and a beta of -0.31.

Insider Transactions at Palvella Therapeutics

In related news, Director Elaine J. Heron acquired 2,400 shares of Palvella Therapeutics stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $500,000.00. Following the transaction, the director directly owned 187,171 shares in the company, valued at $23,396,375. This represents a 2.18% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Millennium Management LLC bought a new position in shares of Palvella Therapeutics in the first quarter valued at approximately $7,553,000. Goldman Sachs Group Inc. bought a new position in Palvella Therapeutics during the 1st quarter valued at $533,000. Geode Capital Management LLC increased its position in shares of Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after purchasing an additional 79,787 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics during the 2nd quarter valued at $37,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: European Patent Office granted Palvella a patent covering its QTORIN™ rapamycin program, strengthening intellectual property protection for the lead product candidate and potentially extending commercial exclusivity if approved. European Patent Office grants Palvella patent for QTORIN rapamycin
• Positive Sentiment: HC Wainwright raised its price target on PVLA from $255 to $270 and reiterated a Buy rating — a sizable analyst upgrade that signals strong sell‑side conviction and could attract momentum buyers. Benzinga
• Positive Sentiment: Palvella appointed Jennifer J. McDonough as SVP of Market Access and Patient Services, bringing commercial/ramp experience from a recent rare-disease launch — a hire that supports future launch and reimbursement planning. Palvella Therapeutics Strengthens Leadership Team
• Neutral Sentiment: Company will report full-year 2025 results and host a corporate update on March 31 (pre-market) with a conference call — a scheduled disclosure that could move the stock depending on revenue, cash burn, guidance, or program updates. Palvella Therapeutics to Host Full-Year 2025 Financial Results
• Neutral Sentiment: Short-interest notices in late March show data anomalies (reported 0 shares and NaN increases across multiple reports), suggesting the short-interest picture is unclear and not a current pressure point based on available filings. (Monitor official exchanges for corrected filings.)
• Negative Sentiment: Insider activity: the COO recently sold roughly $507K of shares — a near-term negative signal for some investors, though company insiders have also made purchases in the last six months. Insider Selling: Palvella Therapeutics COO Sells Stock

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.